US Stock MarketDetailed Quotes

EDIT Editas Medicine

Watchlist
  • 1.250
  • -0.050-3.85%
Close Mar 28 16:00 ET
  • 1.290
  • +0.040+3.20%
Post 20:01 ET
103.72MMarket Cap-0.43P/E (TTM)

Editas Medicine Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
Total revenue
-58.64%32.31M
-49.03%30.6M
-98.86%61K
-82.23%513K
-88.48%1.14M
296.32%78.12M
818.74%60.05M
12,604.76%5.34M
-54.62%2.89M
45.49%9.85M
Operating revenue
-58.64%32.31M
-49.03%30.6M
-98.86%61K
-82.23%513K
-88.48%1.14M
296.32%78.12M
818.74%60.05M
12,604.76%5.34M
-54.62%2.89M
45.49%9.85M
Cost of revenue
Gross profit
Operating expense
9.68%271.23M
-22.67%64.97M
18.43%65.73M
54.14%72.42M
12.03%68.13M
0.67%247.3M
20.05%84.01M
-3.58%55.5M
-22.47%46.98M
5.72%60.81M
Selling and administrative expenses
3.35%71.99M
13.14%16.35M
20.69%18.09M
5.84%18.21M
-15.95%19.34M
-1.49%69.65M
-19.62%14.46M
-7.69%14.99M
1.56%17.2M
17.72%23.01M
-General and administrative expense
3.35%71.99M
13.14%16.35M
20.69%18.09M
5.84%18.21M
-15.95%19.34M
-1.49%69.65M
-19.62%14.46M
-7.69%14.99M
1.56%17.2M
17.72%23.01M
Research and development costs
12.16%199.25M
-30.11%48.61M
17.59%47.64M
82.04%54.21M
29.05%48.79M
1.54%177.65M
33.77%69.56M
-1.97%40.51M
-31.79%29.78M
-0.45%37.8M
Operating profit
-41.22%-238.92M
-43.40%-34.36M
-30.91%-65.67M
-63.07%-71.9M
-31.46%-66.99M
25.12%-169.18M
62.23%-23.96M
12.79%-50.16M
18.70%-44.09M
-0.42%-50.96M
Net non-operating interest income expense
-19.95%14.06M
-76.46%1.2M
-31.38%3.53M
12.75%4.3M
43.49%5.04M
218.34%17.57M
88.13%5.1M
186.89%5.14M
597.99%3.81M
648.19%3.51M
Non-operating interest income
-19.95%14.06M
-76.46%1.2M
-31.38%3.53M
12.75%4.3M
43.49%5.04M
218.34%17.57M
88.13%5.1M
186.89%5.14M
597.99%3.81M
--3.51M
Other net income (expense)
-662.78%-12.24M
-5K
85.71%-1K
100.38%6K
-1.6M
-14K
-102.98%-7K
-576.92%-1.58M
Special income (charges)
---12.23M
----
----
----
----
--0
----
----
----
----
-Less：Restructuring and merger&acquisition
--12.23M
----
----
----
----
--0
----
----
----
----
Other non- operating income (expenses)
99.81%-3K
----
---5K
85.71%-1K
100.38%6K
---1.6M
---14K
----
-102.98%-7K
-576.92%-1.58M
Income before tax
-54.74%-237.09M
-140.52%-45.4M
-38.03%-62.14M
-67.80%-67.61M
-26.34%-61.95M
30.49%-153.22M
68.93%-18.87M
19.21%-45.02M
24.63%-40.29M
2.93%-49.04M
Income tax
Net income
-54.74%-237.09M
-140.52%-45.4M
-38.03%-62.14M
-67.80%-67.61M
-26.34%-61.95M
30.49%-153.22M
68.93%-18.87M
19.21%-45.02M
24.63%-40.29M
2.93%-49.04M
Net income continuous Operations
-54.74%-237.09M
-140.52%-45.4M
-38.03%-62.14M
-67.80%-67.61M
-26.34%-61.95M
30.49%-153.22M
68.93%-18.87M
19.21%-45.02M
24.63%-40.29M
2.93%-49.04M
Minority interest income
Net income attributable to the parent company
-54.74%-237.09M
-140.52%-45.4M
-38.03%-62.14M
-67.80%-67.61M
-26.34%-61.95M
30.49%-153.22M
68.93%-18.87M
19.21%-45.02M
24.63%-40.29M
2.93%-49.04M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-54.74%-237.09M
-140.52%-45.4M
-38.03%-62.14M
-67.80%-67.61M
-26.34%-61.95M
30.49%-153.22M
68.93%-18.87M
19.21%-45.02M
24.63%-40.29M
2.93%-49.04M
Basic earnings per share
-42.57%-2.88
-139.13%-0.55
-36.36%-0.75
-46.43%-0.82
-7.04%-0.76
37.07%-2.02
73.86%-0.23
32.10%-0.55
28.21%-0.56
4.05%-0.71
Diluted earnings per share
-42.57%-2.88
-139.13%-0.55
-36.36%-0.75
-46.43%-0.82
-7.04%-0.76
37.07%-2.02
73.86%-0.23
32.10%-0.55
28.21%-0.56
4.05%-0.71
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023
Total revenue -58.64%32.31M-49.03%30.6M-98.86%61K-82.23%513K-88.48%1.14M296.32%78.12M818.74%60.05M12,604.76%5.34M-54.62%2.89M45.49%9.85M
Operating revenue -58.64%32.31M-49.03%30.6M-98.86%61K-82.23%513K-88.48%1.14M296.32%78.12M818.74%60.05M12,604.76%5.34M-54.62%2.89M45.49%9.85M
Cost of revenue
Gross profit
Operating expense 9.68%271.23M-22.67%64.97M18.43%65.73M54.14%72.42M12.03%68.13M0.67%247.3M20.05%84.01M-3.58%55.5M-22.47%46.98M5.72%60.81M
Selling and administrative expenses 3.35%71.99M13.14%16.35M20.69%18.09M5.84%18.21M-15.95%19.34M-1.49%69.65M-19.62%14.46M-7.69%14.99M1.56%17.2M17.72%23.01M
-General and administrative expense 3.35%71.99M13.14%16.35M20.69%18.09M5.84%18.21M-15.95%19.34M-1.49%69.65M-19.62%14.46M-7.69%14.99M1.56%17.2M17.72%23.01M
Research and development costs 12.16%199.25M-30.11%48.61M17.59%47.64M82.04%54.21M29.05%48.79M1.54%177.65M33.77%69.56M-1.97%40.51M-31.79%29.78M-0.45%37.8M
Operating profit -41.22%-238.92M-43.40%-34.36M-30.91%-65.67M-63.07%-71.9M-31.46%-66.99M25.12%-169.18M62.23%-23.96M12.79%-50.16M18.70%-44.09M-0.42%-50.96M
Net non-operating interest income expense -19.95%14.06M-76.46%1.2M-31.38%3.53M12.75%4.3M43.49%5.04M218.34%17.57M88.13%5.1M186.89%5.14M597.99%3.81M648.19%3.51M
Non-operating interest income -19.95%14.06M-76.46%1.2M-31.38%3.53M12.75%4.3M43.49%5.04M218.34%17.57M88.13%5.1M186.89%5.14M597.99%3.81M--3.51M
Other net income (expense) -662.78%-12.24M-5K85.71%-1K100.38%6K-1.6M-14K-102.98%-7K-576.92%-1.58M
Special income (charges) ---12.23M------------------0----------------
-Less：Restructuring and merger&acquisition --12.23M------------------0----------------
Other non- operating income (expenses) 99.81%-3K-------5K85.71%-1K100.38%6K---1.6M---14K-----102.98%-7K-576.92%-1.58M
Income before tax -54.74%-237.09M-140.52%-45.4M-38.03%-62.14M-67.80%-67.61M-26.34%-61.95M30.49%-153.22M68.93%-18.87M19.21%-45.02M24.63%-40.29M2.93%-49.04M
Income tax
Net income -54.74%-237.09M-140.52%-45.4M-38.03%-62.14M-67.80%-67.61M-26.34%-61.95M30.49%-153.22M68.93%-18.87M19.21%-45.02M24.63%-40.29M2.93%-49.04M
Net income continuous Operations -54.74%-237.09M-140.52%-45.4M-38.03%-62.14M-67.80%-67.61M-26.34%-61.95M30.49%-153.22M68.93%-18.87M19.21%-45.02M24.63%-40.29M2.93%-49.04M
Minority interest income
Net income attributable to the parent company -54.74%-237.09M-140.52%-45.4M-38.03%-62.14M-67.80%-67.61M-26.34%-61.95M30.49%-153.22M68.93%-18.87M19.21%-45.02M24.63%-40.29M2.93%-49.04M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -54.74%-237.09M-140.52%-45.4M-38.03%-62.14M-67.80%-67.61M-26.34%-61.95M30.49%-153.22M68.93%-18.87M19.21%-45.02M24.63%-40.29M2.93%-49.04M
Basic earnings per share -42.57%-2.88-139.13%-0.55-36.36%-0.75-46.43%-0.82-7.04%-0.7637.07%-2.0273.86%-0.2332.10%-0.5528.21%-0.564.05%-0.71
Diluted earnings per share -42.57%-2.88-139.13%-0.55-36.36%-0.75-46.43%-0.82-7.04%-0.7637.07%-2.0273.86%-0.2332.10%-0.5528.21%-0.564.05%-0.71
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion--------Unqualified Opinion--------
Market Insights
U.S Tech Companies U.S Tech Companies

U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
Cisco
CSCO
-0.88%
NVIDIA
NVDA
-1.58%
Broadcom
AVGO
-1.67%
Taiwan Semiconductor
TSM
-1.78%
ASML Holding
ASML
-2.32%

Unlock the Full List

Investment Theme Gene Editing
Gene Editing
Intraday-1.92%